You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物(06185.HK)公佈業績:2022年內虧損9.65億元
格隆匯 03-27 22:37

格隆匯3月27日丨康希諾生物(06185.HK)發佈公吿,截至2022年12月31日止年度,集團錄得營業總收入約人民幣10.31億元(2021年:人民幣43億元)。減少主要因集團的疫苗產品價格變動及隨着全球COVID-19疫苗接種率增長變慢使得海外市場對COVID-19疫苗需求減少導致。2022年度,集團錄得毛損約人民幣1.867億元(2021年:毛利人民幣30.02億元),主要因為集團的疫苗產品價格變動及COVID-19疫苗產品存貨的有關撇減增加,對毛利產生負面影響。年內虧損人民幣9.65億元,上年同期年內利潤人民幣19.07億元,基本及稀釋每股虧損人民幣3.68元。

集團的研發開支由2021年度的約人民幣8.79億元減少11.4%至2022年度的約人民幣7.78億元,主要由於集團研發疫苗的臨牀試驗及測試費減少約人民幣2.29億元。有關減少與集團的業務發展及研發進度相符,因為集團已成功於2021年將克威莎®商業化,且其他在研疫苗也取得不同研發進展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account